NovaBridge Biosciences (NBP) Equity Ratio (2018 - 2025)

NovaBridge Biosciences (NBP) has 8 years of Equity Ratio data on file, last reported at 0.89 in Q4 2025.

• Equity Ratio for Q4 2025 came in at 0.89, down 6.28% year-over-year; the trailing twelve-month figure through Dec 2025 was 0.89 (down 6.28% YoY), and the FY2025 annual result was 0.89, down 6.28% from the prior year.
• Equity Ratio fell to 0.89 in Q4 2025 per NBP's latest filing, from 0.95 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.95 in Q2 2025 and troughed at 0.66 in Q4 2023.
• A 5-year average of 0.85 and a median of 0.89 in 2025 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2023 and 2024: Equity Ratio decreased 13.4% in 2023, then jumped 43.84% in 2024.
• A 5-year view of Equity Ratio shows it stood at 0.81 in 2021, then fell by 12.25% to 0.71 in 2022, then retreated by 7.95% to 0.66 in 2023, then jumped by 43.84% to 0.95 in 2024, then fell by 6.28% to 0.89 in 2025.
• Business Quant data shows NBP's Equity Ratio at 0.89 in Q4 2025, 0.95 in Q2 2025, and 0.95 in Q1 2025.